ExploreWatchlistsPricing
  1. JP-listed companies
  2. DAIICHI SANKYO COMPANY, LIMITED
  3. Financials
  4. Revenue

DAIICHI SANKYO COMPANY, LIMITED (4568)

Market cap
¥5.21T
P/E ratio
17.6x
Daiichi Sankyo is a global pharmaceutical company that researches, develops and sells prescription drugs and over-the-counter medicines worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue (Million JPY)YoY (%)
Mar 31, 20251,886,256+17.77%
Mar 31, 20241,601,688+25.28%
Mar 31, 20231,278,478+22.36%
Mar 31, 20221,044,892+8.56%
Mar 31, 2021962,516-1.96%
Mar 31, 2020981,793+5.60%
Mar 31, 2019929,717-3.17%
Mar 31, 2018960,195+0.53%
Mar 31, 2017955,124-3.18%
Mar 31, 2016986,446+7.30%
Mar 31, 2015919,372-17.82%
Mar 31, 20141,118,764+12.12%
Mar 31, 2013997,852+6.30%
Mar 31, 2012938,677

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat